Keywords: CXCR4 CXCL12 SDF1 Chemokine Opioid-induced hyperalgesia a b s t r a c t Morphine and related compounds are the first line of therapy in the treatment of moderate to severe pain. Over time, individuals taking opioids can develop an increasing sensitivity to noxious stimuli, even evolving into a painful response to previously non-noxious stimuli (opioid-induced hyperalgesia; OIH). The mechanism underlying OIH is not well understood although complex intracellular neural mechanisms, including opioid receptor desensitization and down-regulation, are believed to be major mechanisms underlying OIH. However, OIH may also be associated with changes in gene expression. A growing body of evidence suggests that cellular exposure to mu agonists upregulate chemokines/receptors and recent work from our laboratory implicates chemokine upregulation in a variety of neuropathic pain behaviors. Here we characterized the degree to which chemokines/receptors signaling is increased in primary afferent neurons of the dorsal root ganglion (DRG) following chronic morphine sulfate treatment and correlated these changes with tactile hyperalgesic behavior in rodents. We demonstrate that mRNA expression of the chemokine, stromal-derived factor-1 (SDF1/CXCL12) is upregulated following morphine treatment in sensory neurons of the rat. The release of SDF1 was found to be constitutive when compared with the activity dependent release of the C-C chemokine, monocyte chemoattractant protein-1 (MCP1/CCL2) in a line of F11 neuroblastoma-sensory neuron hybrid cells. We further determined that there is pronounced CXCR4 expression in satellite glial cells and following morphine treatment, increased functional CXCR4 expression in sensory neurons of the DRG. Moreover, intraperitoneal administration of the specific CXCR4 antagonist, AMD3100, completely reversed OIH in the rat. Taken together; the data suggest that opioidinduced SDF1/CXCR4 signaling is central to the development of long lasting OIH and that receptor antagonists represent a promising novel approach to the management of the side effects associated with the use of opioids for chronic pain management.
Introduction
Opioids such as morphine currently represent the best option for the management of moderate to severe trauma induced, perioperative and cancer pain. Opioid compounds are also increasingly being used for non-cancer associated chronic pathological pain. However, prolonged administration of opioids is associated with significant problems including the development of anti-nociceptive tolerance, wherein higher doses of the drug are required over time to elicit the same degree of analgesia. Repeated administration of higher doses of morphine or fentanyl also results in increasing pain sensitivity, a syndrome clinically known as opioid-induced hyperalgesia (OIH) (Angst et al., 2003; Arner et al., 1988; Singla et al., 2007) . This increased pain is usually experienced at different locations from the original site of injury (Ossipov et al., 2004) .
While it is thought that opioids modulate tactile hyperalgesia solely by acting at neuronal opioid receptors, administration of chronic morphine is also known to induce a rapid increase in the expression of the proinflammatory cytokines such as TNFa, IL1b and IL-6 in a number of cell types within the nervous system (Johnston et al., 2004) . These proinflammatory cytokines are powerful pain enhancing proteins that may, in turn, suppress acute opioid analgesia and contribute to the apparent loss of opioid analgesia upon repeated opioid administration (''tolerance'') (Hutchinson et al., 2008) . The family of pro-nociceptive cytokines includes chemotactic cytokines (chemokines). Proalgesic effects of chemokines have been implicated in both acute and chronic tactile hyperalgesic behavior (Abbadie et al., 2003; Bhangoo et al., 2007a,b; Johnston et al., 2004; Jung et al., 2009; Menetski et al., 2007; Milligan et al., 2004; Oh et al., 2001; Wang et al., 2008; White et al., 2005; Xie et al., 2006) . However, the degree to which chronic morphine treatment alters gene expression of
